Olga Granaturova

Olga Granaturova is a prominent figure in the biotechnology and pharmaceutical industries, currently serving as the Co-Founder and President of PriveBio, a stealth-mode biotechnology company based in Boston, Massachusetts. She has over 25 years of experience in the biopharma sector, having held various leadership roles that span the entire value chain from research and development to commercialization.

Professional Background

Granaturova's career includes significant positions at major pharmaceutical companies such as Pfizer, Bristol Myers Squibb, and Merck. She has co-founded multiple biotech firms, including Parthenon Therapeutics, where she served as Chief Operating Officer until early 2023. At Parthenon, she was instrumental in developing novel anti-cancer therapies aimed at improving treatment efficacy for patients.123

In addition to her role at PriveBio, she is also the Chief Operating Officer and Chief Business Officer at Normunity, a company focused on precision immuno-oncology therapies. Her expertise encompasses corporate strategy, business development, fundraising, and mergers and acquisitions.24

Achievements and Recognition

Olga Granaturova has been recognized for her contributions to entrepreneurship and innovation in the life sciences. In 2022, she was named to Inc. Magazine's Female Founders 100 List, which honors women whose work is making a significant impact globally.13 She is also a co-founder of Brighter Ventures, a nonprofit organization dedicated to supporting women-led entrepreneurship and education in AI lifesciences.1

Education

Granaturova holds a Bachelor of Science in Pharmaceutical Sciences from the University at Buffalo and a TRIUM Global Executive MBA from a consortium of prestigious institutions including NYU Stern School of Business, HEC Paris, and the London School of Economics.14

Board Memberships

She actively participates on the boards of several organizations, including Incendia Therapeutics and Coucou Nous Voilou, which focuses on pediatric oncology.12

Olga Granaturova's extensive experience and commitment to advancing healthcare innovations position her as a key leader in the biotechnology field.